progression is still incompletely understood. [4] Thus, markers for progression and metastatic capacity of cSCC are in need. [7] There is increasing evidence that the role of tumor microenvironment presents a significant role in initiation and progression of cSCC. The composition of epidermal basement membrane and dermal extracellular matrix, influx of inflammatory cells and presence of microbial structures have been revealed to affect cSCC progression. [8] [9] [10] Epidermal keratinocytes are connected by four types of cell junctions: desmosomes, adherence junctions, gap junctions and tight junctions (TJ). TJs are localized in granular cell layer, whereas other cell junctions can be found between keratinocytes in all viable layers of the epidermis. [11, 12] TJs regulate movement of macromolecules, ions and inflammatory cells in simple epithelia. [13] TJs consist of transmembrane proteins occludin and variable combinations of claudins, and peripheral plaque proteins, such as TJ proteins (TJP) 1-3 (zona occludens, ZO), which connect TJs to actin cytoskeleton. Phosphorylation of occluding, claudins and ZO-1 regulates the permeability of TJs. [14] The expression and localization of TJ proteins has been shown to be altered in various types of cancers in a stage and tumor-specific manner. [15] In addition, TJ molecules have been shown to be involved in cell-cell adhesion, apoptosis and tumor invasion. [16] Claudin family consists of more than 23 members expressed in tissue-specific manner in various normal and malignant tissues. [17] Normal human epidermis contains claudin-1, claudin-4 and claudin-7. [16] Claudin-11, also known as oligodendrocyte-specific protein (OSP), is concentrated in central nervous system myelin, [18] and it is expressed in Sertoli cells in testes at all stages of the seminiferous epithelial cycle, [19] while it has not been detected in human epidermal TJs. [16] Increased expression of claudin-3 and claudin-4 has been revealed in malignant tumors including breast, colorectal, prostate and ovarian cancers. [15] During cSCC progression, decreased claudin-1 expression and increased claudin-2 expression have been noted in actinic keratosis (AK) and cSCC. [20] Furthermore, the expression of claudin-4 has been shown to be associated with keratinization in cSCC and cSCC in situ (cSCCIS). [21] In this study, we have examined the role of TJ components in the progression of cSCC. The results show that the expression of claudin-11 is specifically upregulated in primary cSCC cell lines, whereas the expression is low or absent in NHEKs and metastatic cSCC cell lines. 
| MATERIALS AND METHODS

| Ethical issues
Approval for use of archival tissue specimens and the collection of normal skin and cSCC tissues was obtained from the Ethics Committee of 
| Cell cultures
Human cSCC cell lines were established from surgically removed primary (n=5) and metastatic (n=3) cSCCs and cultured in DMEM supplemented with 6 nmol/L glutamine, non-essential amino acids and 10% FCS as described previously. [22] The authentication of cell lines was performed by STR DNA profiling. [23] Normal human epidermal keratinocytes (NHEK, n=4) originated from normal skin obtained from breast reduction operations at the Department of Surgery, Turku University Hospital, Turku, Finland. Additional NHEKs (NHEK-PC)
were purchased from PromoCell (Heidelberg, Germany). NHEKs were cultured in Keratinocyte Basal Medium 2 (PromoCell GmbH), as previously described. [24] For p38 MAPK inhibitor treatment, the cells were first serum-starved for 24 hours, followed by treatment with p38 MAPK inhibitors SB203580 (10 μmol/L; Calbiochem, Darmstadt, Germany) or BIRB796 (10 μmol/L; Axion Medchem, Groningen, the Netherlands) in 10% DMEM for 24 hours.
| Oligonucleotide array-based expression and RNA sequencing analysis
RNA extraction was performed as described previously. [24] For RNA sequencing (RNA-seq), total RNA was isolated using miRNAeasy Mini Biotechnology, Turku, Finland. [25] The samples were processed with the SOLiD 3Plus instrument with 35 bp read length. The colourspace reads were aligned against the human reference genome (GRCh37 assembly) using the standard whole transcriptome pipeline and the colourspace alignment tool (Applied Biosystems). The data were normalized as described previously (25) . The microarray data (accession number GSE66368) and RNA-seq data (accession number GSE66412)
are available at the Gene Expression Omnibus (GEO, NCBI; http:// www.ncbi.nlm.nih.gov/geo/).
| Quantitative real-time PCR
Preparation of cDNA was performed as described previously. [25] Quantitative real-time PCR (qRT-PCR) analysis of cDNA samples was performed with specific primers and fluorescent probes for CLDN11: forward primer 5′-CGTGGGTGGCTGTGTCATC-3′, reverse primer 5′-GAGCCCGCAGTGTAGTAGAAAC-3′ and probe 5′-CTGCTGCGCTGGAGATGCCC -3′. Primers and probes were purchased from Oligomer (Helsinki, Finland). β-actin was used as a control. [22, 26] Applied Biosystems 7900HT Fast Real-Time PCR System was used to perform qRT-PCR. AxioVision Release 4.9.1 software (Carl Zeiss, Jena, Germany) was used for imaging the samples. was used. [24] Rabbit polyclonal claudin-11 (HPA013166; Sigma) antibody was used. As a positive control for claudin-11 staining, mouse brain tissue samples were used. Claudin-11 staining was analysed by three observers (L.N., P.R. and M.K.).
| Immunofluorescence stainings
| Tissue samples and immunohistochemistry
| Western blot analysis
For Western blot analysis, cell lysates were fractionated in 10% SDS-polyacrylamide gel and transferred onto nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ, USA), as previously described. [25] The following antibodies were used in Western blot- 
| Adenoviral gene delivery
Cutaneous SCC cells were infected with adenoviral vectors at MOI 600, for 6 hours after which the medium was changed, as previously described. [28] Recombinant adenoviruses for dominant negative mutants of p38δ (RAdp38δAF) and p38α (RAdp38αAF) [29] were kindly provided by Dr. Jiahuai Han (Scripps Research Institute, La Jolla, CA, USA).
Recombinant adenovirus RAdLacZ, which contains the Escherichia coli β-galactosidase gene under the control of CMV IE promoter, [30] was kindly provided by Dr. Gavin W. G. Wilkinson (University of Cardiff, UK).
| siRNA knock-down experiments
The following siRNAs (all from Qiagen) were used: for claudin-11
Hs_CLDN11_5 (sense 5′-GCAAGUGAGUAUAACUCUATT-3′, antisense 5′-UAGAGUUAUACUCACUUGCAC-3′), for claudin-11
Hs_CLDN11_7 (sense 5′-GGUAUAUCAGUAUCUGAGATT-3′, antisense 5′-UCUCAGAUACUGAUAUACCAT-3′), for p38α Hs_MAPK 14_6 (sense 5′-GAGAACUGCGGUUACUUAATT-3′, antisense 5′-UUAA GUAACCGCAGUUCUCTG-3′), for p38δ Hs_MAPK13_5 (sense 5′-GGAGUGGCAUGAAGCUGUATT-3′, antisense 5′-UACAGCUUC AUGCCACUCCGG-3′). Non-specific siRNA (Qiagen) was used as a negative control. cSCC cell lines were transfected with siRNA using siLentFect™ Lipid Reagent (Bio-Rad Laboratories, Hercules, CA, USA), as previously described. [31] For Western blot analysis, cells were incubated 72 hours after siRNA transfections and total cell lysates were collected. 
| Cell proliferation assays
| Invasion assays
To study the effect of claudin-11 in cSCC cell invasion, cells were trans- and UT-SCC118).
| RESULTS
| The expression of claudin-11 is upregulated in primary cSCC cell lines
The expression of TJ component mRNAs in primary (n=5) and meta- 
| Tumor cell-specific expression of claudin-11 in cSCC in vivo
| Expression of claudin-11 in cSCC cells is regulated by p38δ
Our previous studies have demonstrated basal activation of p38
MAPKs in cSCC cells in culture and in vivo. [22] We have also shown that p38δ MAPK regulates the expression of ZO-1 in both NHEKs and cSCC cells. [27] In this respect, we investigated the role of p38 MAPK signalling in regulation of claudin-11 expression in cSCC cells. All cSCC cell lines and NHEKs studied expressed both p38α and p38δ isoforms ( Figure 3A) . [22] The role of p38 MAPK pathway in the regulation of the expression of junction proteins was first investigated by treating the cells with BIRB796 (10 μmol/L), a specific inhibitor of all four p38 isoforms (α, β, γ, δ) and with SB203580 (10 μmol/L), an inhibitor of p38α and p38β. Treatment with BIRB796 potently inhibited the expression of claudin-11, whereas SB203580 had no marked effect revealing the role of p38δ in the regulation of claudin-11 expression ( Figure 3B ). As shown previously, BIRB796 and SB203580 also inhibited the expression of ZO-1 in cSCC cells ( Figure 3B ). [27] Treatment with SB203580 or BIRB796 had no effect on claudin-1 or β-catenin levels in cSCC cells ( Figure 3B ). The role of p38δ in the regulation of claudin-11 was further examined using specific siRNAs for silencing of p38α and p38δ
( Figure 3C ). Knock-down of both p38α and p38δ inhibited the expression of ZO-1, but only silencing of p38δ inhibited the expression of claudin-11 in cSCC cells ( Figure 3C ). In contrast, knock-down of p38α or p38δ had no effect on the expression of claudin-1 or β-catenin in cSCC cell lines ( Figure 3C ). To confirm these results, the function of p38α and p38δ was inhibited by adenoviral expression of dominant negative mutants of p38α (p38αAF) and p38δ (p38δAF). Inhibition of p38δ downregulated the expression of claudin-11 in cSCC cell lines, whereas inhibition of p38α had no effect ( Figure 3D ).
| Claudin-11 regulates the invasion of cSCC cells
To elucidate the functional role of claudin-11 in cSCC cells, specific small interfering RNAs (claudin-11 siRNA_5 and claudin-11 siRNA_7, 75 nmol/L) were used to knock down the expression of claudin-11
( Figure 4A, Fig. S1A ). Cutaneous SCC cultures transfected with control siRNA, or claudin-11 siRNAs (75 nmol/L) were incubated for 48 hours and the invasion of UT-SCC12A and UT-SCC118 cells through matrigel was subsequently determined. Knock-down of claudin-11 significantly increased the invasion of cSCC cells through matrigel ( Figure 4B, Fig.   S1B ), but in the same time points, knock-down of claudin-11 had no effect on the number of viable cSCC cells (Fig. S2) . 
| DISCUSSION
In this study, we have examined the expression of TJ molecules in cSCC, the most common metastatic skin cancer. [4] The results of the in NHEKs, in accordance with previous findings. [32] On the basis of these findings, claudin-11 was selected for further characterization to specify its role in the progression of cSCC.
Immunohistochemistry analysis of a large panel of tissue samples from cSCCs revealed specific staining for claudin-11 in cell-cell contacts of keratinizing tumor cells in well and moderately differentiated cSCCs in vivo, whereas no staining was detected in poorly differentiated cSCCs. The localization pattern of claudin-11 in cSCC was similar to that previously reported for claudin-4, and ZO-1 in cSCC [20] and resembles that of normal epidermis where TJs are present in welldifferentiated cells in the granular layer. Altered expression of TJ molecules, for example claudins and ZO-1, has been described in various cancer types. [15] In addition, reduced expression of TJs and alterations in their function has been demonstrated during carcinogenesis associated with poor differentiation of tumors. [33] In this study, all tissue samples from preinvasive cSCCs (cSCCIS) and premalignant lesions (AK), as well as from benign skin tumors (SK) were negative for claudin-11 staining indicating that the induction of CLDN11 is associated with progression of cSCC to the invasive stage.
Cutaneous SCC cells have been shown to express p38α and p38δ
MAPK isoforms, and basal activation of p38 MAPK pathway promotes cSCC cell invasion. [22, 34] The role for p38δ in cutaneous carcinogenesis has also been demonstrated in knockout mouse model of p38δ. [34, 35] Furthermore, we have previously noted that the expression of ZO-1 is regulated by p38δ in NHEKs and cSCC cells. [27] The results of the present study demonstrate that claudin-11 expression in cSCC cells is specifically dependent on the activity of p38δ. It is therefore possible that activation of p38δ in the early stage of cSCC growth mediates induction of claudin-11 expression in cSCC cells in vivo.
In the present study, claudin-11 was absent in metastatic cSCC cell lines and in less-differentiated cSCC tumors in vivo. In addition, our results show that invasion of cSCC cells through matrigel is enhanced, when claudin-11 expression is silenced. These findings are also supported by previous studies in which the expression of claudin-11 was shown to decrease the invasiveness of bladder and gastric cancer cells in vitro. [36, 37] Loss of claudin-11 could be due to epigenetic regulation observed for claudin family in human cancers. Methylation of CLDN1 and CLDN3 has been detected in colon and breast cancer and oesophageal and hepatocellular carcinoma, respectively. [38, 39] Moreover, methylation of CLDN4 and CLDN5 genes has been demonstrated in bladder and pancreatic cancer. [40, 41] Methylation of CLDN11 has been detected in malignant melanoma, and methylation of this gene is significantly more frequent in skin metastases than in brain metastases. [42] Expression of claudins is altered in various epithelial cancers in a stage-and tumor-specific manner making claudin family members potential biomarkers for these cancers. [15] During progression of cSCC, decrease in the expression of claudin-1 and increase in the expression of claudin-2 have been noted. [20] In addition, downregulation or loss of claudin-1 has been shown to promote brain metastasis of melanoma, and it has been suggested that expression of claudin-1 could serve as a prognostic marker for melanoma patients with a high risk of brain metastasis. [43] Our results reveal specific regulation of claudin-11 expression during cSCC progression and warrant further evaluation of the loss of claudin-11 as a biomarker for aggressive behaviour of cSCC.
